GeneDx (NASDAQ:WGS) Trading Up 7.9% – Here’s What Happened

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) traded up 7.9% during trading on Tuesday . The company traded as high as $62.70 and last traded at $65.3090. Approximately 220,150 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 992,343 shares. The stock had previously closed at $60.54.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: GeneDx received an average analyst rating of “Moderate Buy,” which may be helping support the stock despite continuing litigation concerns. GeneDx Receives Moderate Buy Analyst Rating
• Neutral Sentiment: Multiple law firms reminded investors that August 3, 2026 is the deadline to seek appointment as lead plaintiff in a securities class action covering purchases of WGS securities from April 16, 2025, through May 4, 2026. The notices largely repeat the same case and do not represent separate lawsuits or new operating developments. Portnoy Law Firm Class Action Notice
• Negative Sentiment: The lawsuit alleges GeneDx misled investors about the expected performance and financial impact of its Fabric Genomics acquisition. Promotional claims reportedly described Fabric as a way to create recurring, software-based revenue, while subsequent disclosures included a $31.2 million write-off and were associated with an alleged 49% stock decline. If the claims progress, GeneDx could face legal costs, settlement exposure, and additional scrutiny of its acquisition strategy and disclosures. Robbins LLP GeneDx Securities Class Action Notice

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Canaccord Genuity Group set a $75.00 price objective on shares of GeneDx and gave the stock a “buy” rating in a research note on Tuesday, May 5th. TD Cowen reaffirmed a “buy” rating on shares of GeneDx in a research note on Wednesday, July 15th. Wells Fargo & Company reiterated an “overweight” rating and issued a $75.00 target price (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Zacks Research cut shares of GeneDx from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Finally, BTIG Research decreased their price target on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.43.

GeneDx Stock Performance

The company has a market cap of $1.89 billion, a price-to-earnings ratio of -23.74 and a beta of 1.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The stock has a 50-day moving average price of $59.11 and a 200 day moving average price of $71.49.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The business had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same quarter last year, the firm earned ($0.23) EPS. As a group, analysts anticipate that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Casdin Capital, Llc purchased 185,000 shares of GeneDx stock in a transaction dated Tuesday, May 19th. The stock was bought at an average price of $42.60 per share, for a total transaction of $7,881,000.00. Following the completion of the acquisition, the director directly owned 3,367,164 shares of the company’s stock, valued at $143,441,186.40. This represents a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Keith A. Meister acquired 533,758 shares of the stock in a transaction dated Thursday, May 7th. The shares were bought at an average cost of $37.86 per share, with a total value of $20,208,077.88. Following the transaction, the director directly owned 3,761,908 shares of the company’s stock, valued at $142,425,836.88. This represents a 16.53% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 2,256,420 shares of company stock worth $93,144,340 and sold 21,699 shares worth $1,295,646. Insiders own 25.17% of the company’s stock.

Hedge Funds Weigh In On GeneDx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its holdings in GeneDx by 4.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after purchasing an additional 52,322 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of GeneDx by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock worth $154,650,000 after buying an additional 18,647 shares during the period. Franklin Resources Inc. boosted its position in shares of GeneDx by 60.4% during the fourth quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after buying an additional 411,607 shares during the period. Westfield Capital Management Co. LP grew its holdings in shares of GeneDx by 87.1% during the fourth quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after buying an additional 474,167 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of GeneDx by 59.2% during the fourth quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after buying an additional 292,394 shares in the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.